Last reviewed · How we verify
NCT04659707
Hyperpolarized 129Xe MRI of Survivors of COVID-19
Phase 1 trial testing Hyperpolarized Xe129 in Covid19 in 20 participants. Participants enrolled and being followed up; not accepting new ones.
1 January 2025
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 22 February 2021 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized Xe129 — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
University of Kansas Medical Center
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04659707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperpolarized Xe129
Trials testing the same drug.
- NCT06122922 — Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) · Phase 2 · withdrawn
- NCT06038630 — 129Xe MRI Cardiopulmonary · Phase 2 · recruiting
- NCT05766384 — Hyperpolarized 129Xe MRI Lung Health Cohort · recruiting
- NCT05339386 — Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension · active not recruiting
- NCT05204355 — MRI for Screening and Monitoring Scleroderma ILD · active not recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04659707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing